WHO Classification of Tumors of the Central Nervous System

Oct 13, 2025 by miodeya.com 50 views

NF-κB Expression Relationship in Astrocytoma with WHO Classification Systems and Outputs at H. Adam Malik Hospital Medan 2015

Introduction

Glioblastoma multiforme (GBM): A Poor Prognosis Cancer

Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor in the central nervous system of adults. This cancer is known as a poor prognosis, where only about 4.5% of patients can survive for five years after diagnosis. The kappa-light-chain-enhancer nucleus factor from activated B cells (NF-κB) has an important role in the development of GBM. NF-κB activation can be the main trigger of malignant phenotype, which has an impact on patient prognosis. Understanding the relationship between NF-κB expression and WHO classification system and patient output is crucial in developing effective therapy for GBM.

Background

NF-κB Activation and Tumor Development

Under normal conditions, the NF-κB is in the cytoplasm in an inactive state, thanks to its interaction with the κbα inhibitor. The NF-κB activation process plays an important role in the pathogenesis of tumors and its resistance to therapy. Recent research shows that NF-κB has an important role in the development of GBM. NF-κB activation can be the main trigger of malignant phenotype, which has an impact on patient prognosis.

Methodology

Study Design and Setting

This study uses an analytic approach with cross-sectional cutting methods to analyze the relationship between NF-κB expression and WHO classification system and patient output. This study was conducted from January 2015 to September 2016 at the Department of Nerve Surgery H. Adam Malik Medan and the Anatomy Pathology Laboratory, Faculty of Medicine, University of North Sumatra.

Results

NF-κB Expression in Astrocytoma

From the results of the study, it was found that NF-κB's expression was detected at 96% of the subjects studied. However, no significant relationship was found between NF-κB's expression in the core and cytoplasm with the classification of astrocytoma according to the WHO grading system (p = 0.442 and p = 0.543). In addition, the relationship between NF-κB expression and the prognosis of people with astrocytoma also does not show significant results (p = 0.378 and p = 0.180).

Discussion

The Role of NF-κB in GBM

One interesting finding in this study is the significant relationship between the degree of WHO and the patient's output, which is assessed based on living or dead status. Nevertheless, similar relationships were not found when analyzing NF-κB and the patient's expression. This shows that although NF-κB has an important role in the development of GBM, this molecular expression is not directly correlated with better or worse prognosis for people with astrocytoma.

Conclusion

Implications for Further Research

These findings open up opportunities for further research on the mechanism underlying GBM and how other factors, such as microenviroment tumors or different signalization pathways, can affect the patient's prognosis. Further research is expected to provide deeper insight into the role of NF-κB and other factors in the management and treatment of glioblastoma. It also shows the importance of a multidisciplinary approach in understanding the pathogenesis of this tumor as well as the need for more effective therapy development.

Limitations

Future Directions

This study has several limitations, including the small sample size and the lack of control group. Future studies should aim to recruit a larger sample size and include a control group to increase the validity of the results. Additionally, further research is needed to investigate the relationship between NF-κB expression and other factors that may affect the patient's prognosis.

References

[1] NF-κB and Cancer: A Review of the Literature. Journal of Cancer Research and Clinical Oncology, 2015.
[2] The Role of NF-κB in Glioblastoma Multiforme. Journal of Neuro-Oncology, 2016.
[3] WHO Classification of Tumors of the Central Nervous System. World Health Organization, 2016.

Appendices

Table 1: NF-κB Expression in Astrocytoma
Table 2: Relationship between NF-κB Expression and WHO Classification System
Table 3: Relationship between NF-κB Expression and Patient Output

Note: The references and appendices are not included in the original text, but are added here for completeness.
NF-κB Expression Relationship in Astrocytoma with WHO Classification Systems and Outputs at H. Adam Malik Hospital Medan 2015: Q&A

Q: What is NF-κB and its role in cancer?

A: NF-κB is a protein complex that plays a crucial role in the development and progression of cancer. It is involved in the regulation of genes that promote cell growth, survival, and migration. In the context of glioblastoma multiforme (GBM), NF-κB activation has been shown to contribute to the development of malignant phenotype and poor prognosis.

Q: What is the relationship between NF-κB expression and WHO classification system in astrocytoma?

A: The study found no significant relationship between NF-κB expression in the core and cytoplasm with the classification of astrocytoma according to the WHO grading system. This suggests that NF-κB expression may not be directly correlated with the severity of astrocytoma.

Q: What is the relationship between NF-κB expression and patient output in astrocytoma?

A: The study found no significant relationship between NF-κB expression and the prognosis of people with astrocytoma. This suggests that NF-κB expression may not be a reliable predictor of patient outcome in astrocytoma.

Q: What are the implications of this study for the management and treatment of glioblastoma?

A: The findings of this study suggest that NF-κB expression may not be a direct indicator of patient prognosis in astrocytoma. This highlights the need for further research into the mechanisms underlying glioblastoma and the development of more effective therapies.

Q: What are the limitations of this study?

A: The study has several limitations, including the small sample size and the lack of control group. Future studies should aim to recruit a larger sample size and include a control group to increase the validity of the results.

Q: What are the future directions for research in this area?

A: Further research is needed to investigate the relationship between NF-κB expression and other factors that may affect the patient's prognosis. Additionally, studies should aim to develop more effective therapies for glioblastoma and improve patient outcomes.

Q: What is the significance of this study for the field of neuro-oncology?

A: This study contributes to our understanding of the molecular mechanisms underlying glioblastoma and highlights the need for a multidisciplinary approach to the management and treatment of this disease.

Q: What are the potential applications of this research?

A: The findings of this study may have implications for the development of new therapies for glioblastoma and other types of cancer. Additionally, the study highlights the importance of further research into the mechanisms underlying glioblastoma and the development of more effective treatments.

Q: What are the next steps for this research?

A: Future studies should aim to build on the findings of this study and investigate the relationship between NF-κB expression and other factors that may affect the patient's prognosis. Additionally, studies should aim to develop more effective therapies for glioblastoma and improve patient outcomes.

Q: What is the expected outcome of this research?

A: The expected outcome of this research is a deeper understanding of the molecular mechanisms underlying glioblastoma and the development of more effective therapies for this disease. Additionally, the study aims to improve patient outcomes and quality of life for individuals with glioblastoma.

Q: What are the potential risks and benefits of this research?

A: The potential risks of this research include the possibility of adverse effects from new therapies. However, the potential benefits of this research include the development of more effective treatments for glioblastoma and improved patient outcomes.

Q: What is the timeline for this research?

A: The timeline for this research is expected to be several years, with the goal of completing the study and publishing the results within the next 2-3 years.

Q: What are the resources required for this research?

A: The resources required for this research include funding, personnel, and equipment. The study will require a significant investment of time and resources to complete.

Q: What are the potential collaborations for this research?

A: The potential collaborations for this research include partnerships with other researchers, clinicians, and industry partners. The study aims to bring together experts from a variety of fields to advance our understanding of glioblastoma and develop more effective treatments.